Lynx.MD Collaboration with Prometheus Labs to Revolutionize IBD Treatment
Innovative Research for Inflammatory Bowel Disease
Lynx.MD played a critical role in publishing and accepting four industry abstracts for Prometheus Laboratories, through collaboration and the Lynx.MD platform, Prometheus was able to harness de-identified real-world clinical data from Gastro Health to compare inflammatory bowel disease (IBD) surgeries and related expenditures between infliximab dose-optimized patients using therapeutic drug monitoring (TDM) versus a no TDM control group. These comprehensive studies, conducted with real-world data from Gastro Health’s community-based gastroenterology practices, resulted in the submission and poster presentation of four abstracts at major conferences.
Results
4 Published Abstracts
3x Faster Research to Results
Lynx.MD played a critical role in publishing and accepting four industry abstracts for Prometheus Laboratories, through collaboration and the Lynx.MD platform, Prometheus was able to harness de-identified real-world clinical data from Gastro Health to compare inflammatory bowel disease (IBD) surgeries and related expenditures between infliximab dose-optimized patients using therapeutic drug monitoring (TDM) versus a no TDM control group. These comprehensive studies, conducted with real-world data from Gastro Health’s community-based gastroenterology practices, resulted in the submission and poster presentation of four abstracts at major conferences.
Innovative Research for Inflammatory Bowel Disease
Lynx.MD bridges the gap between healthcare providers, medtech, and life sciences companies by providing quick access to real-time, real-world clinical data in a secure environment. Gastro Health, one of the largest regional gastroenterology practices in the country, played a crucial role in supplying data for this groundbreaking research. Working alongside Lynx.MD’s research analytics team, Prometheus Laboratories contributed to the formulation of meaningful research hypotheses, thorough data exploration, and the creation of the final poster submissions.
Efficient and Secure Data Handling
All research was efficiently managed within the Lynx.MD platform, which handled both structured and unstructured data. The data was de-identified and securely stored within the platform, enabling faster access to results. Remarkably, the Lynx.MD platform demonstrated a threefold increase in speed from data collection to abstract submission compared to traditional real-world data methodologies.
Lynx.MD Solution
Through this collaborative effort, Prometheus Labs is pioneering the future of IBD treatment, driving advancements that promise to benefit patients, healthcare providers, and the broader medical community.
Data Aggregation:
Lynx.MD united a decade’s worth of de-identified clinical and patient data related to IBD. This extensive dataset provides invaluable insights into patterns, trends, and effective treatments.
Research:
Leveraging real-world data, Lynx.MD investigated and highlighted the value of the Prometheus Anser® IFX therapeutic drug monitoring test. This research will identify more effective treatment strategies based on actual patient data.
Outcome Enhancement
The collaboration’s insights aim to enhance patient clinical outcomes, improving the quality of life for IBD patients. This initiative potentially reduces hospital stays, complications, and other costly interventions, thereby alleviating the strain on the healthcare system.
Economic Impact:
Optimizing treatments and improving patient outcomes can significantly reduce overall healthcare costs associated with IBD for patients, providers and payers.